WebTotal funding of the company - $457.7M. To connect with MorphoSys employee register on SignalHire. Organization Website: morphosys.com : Social Links: Contact Email: [email protected]: Phone Number: 49-89-899-27-0: MorphoSys industries ... 10K - 50K 42.2B -Genmab . 1999 WebMar 23, 2024 · MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2024. Read more. …
MorphoSys AG (MOR) Stock Price, Quote & News - Stock Analysis
WebApr 13, 2024 · Kapitalquote steigt auf 246 Prozent. Die regulatorische Kapitalquote nach Solvency II von UNIQA, die als Gradmesser für die Kapitalisierung gilt, lag mit 31. Dezember 2024 bei guten 246 Prozent. Das ist, ausgehend von einem hohen Niveau, ein Anstieg um weitere 50 Prozentpunkte. Grund dafür sind die steigenden Zinssätze, die größere ... WebApr 13, 2024 · MorphoSys AG Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update. PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2024. “2024 was a defining year for MorphoSys. We made advances ... jewelry making schools near me
Royalty Pharma Announces $2.025 Billion Strategic Funding
WebMay 12, 2024 · BOSTON, May 12, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced that new data on pelabresib and tafasitamab, marketed in the U.S. as Monjuvi® and in Europe as Minjuvi®, will be presented during the 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024) in Chicago from June 3 – 7, 2024 and the 2024 … WebMar 23, 2024 · Investor Relations. Investor Relations represents MorphoSys and its equity story to the financial market and supports the Company's overall strategic … Web2 days ago · Official Publications. Sector news. MarketScreener Strategies. Communiqués de presse de la société MORPHOSYS AG. 04/04. MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibros.. EQ. 03/27. MorphoSys AG, Repurchase of portion of outstanding convertible bonds due 2025. jewelry making molds for silicone